201039-13-6

Basic information

• Product Name: (R)-TERT-BUTYL 2-(CYANOMETHYL)PYRROLIDINE-1-CARBOXYLATE
• Synonyms: (R)-TERT-BUTYL 2-(CYANOMETHYL)PYRROLIDINE-1-CARBOXYLATE
• CAS NO: 201039-13-6
• Molecular Formula: C11H18N2O2
• Molecular Weight: 210.27
• Mol File: 201039-13-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 327.375 ºC at 760 mmHg
• Flash Point: 151.791 ºC
• Appearance: /
• Density: 1.062 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.478
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-TERT-BUTYL 2-(CYANOMETHYL)PYRROLIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-TERT-BUTYL 2-(CYANOMETHYL)PYRROLIDINE-1-CARBOXYLATE(201039-13-6)
• EPA Substance Registry System: (R)-TERT-BUTYL 2-(CYANOMETHYL)PYRROLIDINE-1-CARBOXYLATE(201039-13-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 201039-13-6(Hazardous Substances Data)

Usage

General Description

(R)-TERT-BUTYL 2-(CYANOMETHYL)PYRROLIDINE-1-CARBOXYLATE is a chemical compound with a molecular formula C12H20N2O2. It is a pyrrolidine derivative with a tert-butyl ester group and a cyanomethyl functional group. (R)-TERT-BUTYL 2-(CYANOMETHYL)PYRROLIDINE-1-CARBOXYLATE may be used as a building block for the synthesis of various pharmaceuticals and agrochemicals. It has potential applications in medicinal chemistry and drug discovery due to its ability to interact with biological targets and modulate various biological processes. Additionally, it may also be used as a precursor for the generation of diverse chemical scaffolds with potential biological activity.

InChI:InChI=1/C11H18N2O2/c1-11(2,3)15-10(14)13-8-4-5-9(13)6-7-12/h9H,4-6,8H2,1-3H3/t9-/m1/s1

Upstream product

• 344-25-2 D-Prolin 
• 1301760-11-1 C₁₅H₂₅NO₅ 
• 773837-37-9 sodium cyanide 
• 128510-88-3 tert-butyl (R)-2-(4-methylbenzenesulfonyloxymethyl)pyrrolidine-1-carboxylate 
• 132482-10-1 (R)-1-<(1,1-dimethylethoxy)carbonyl>-2-pyrrolidinemethanolmethanesulfonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 68832-13-3 D-prolinol 
• 37784-17-1 N-(tert-butoxycarbonyl)-D-proline 
• 59378-81-3 1-(tert-butoxycarbonyl)prolin-2R-ol 
• 151-50-8 potassium cyanide 
• 143-33-9 sodium cyanide 

Downstream Products

• 61350-65-0 (R)-2-(pyrrolidin-2-yl)acetic acid 
• 101555-60-6 2-(R)-carboxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 154887-98-6 (4R,6S)-conioidine A 
• 154887-98-6 (4R,6R)-conioidine A 
• 550378-07-9 tert-butyl (2R)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate 
• 261901-57-9 (R)-3-(2-(2-(4-methyl-piperidin-1-yl)ethyl)-pyrrolidine-1-sulfonyl)-phenol hydrochloride 
• 201038-72-4 (R)-1-(2-(1-(3-benzyloxy-benzenesuylfonyl)-pyrrolidin-2-yl)-ethyl)-4-methyl piperidine 

Relevant articles and documents

Synthesis and Stereochemical Assignment of Conioidine A: DNA- And HSA-Binding Studies of the Four Diastereomers

Conioidine A (1), isolated in 1993 with unknown relative and absolute configuration, was suggested to be a DNA-binding compound by an indirect technique. Four stereoisomers of conioidine A have been synthesized from d- and l-proline, and the natural product has been identified as possessing (4R,6R) absolute configuration. Binding of the conioidine diastereomers to calf thymus DNA (CT DNA) and human serum albumin (HSA) has been investigated by fluorescence spectroscopy and isothermal titration calorimetry (ITC). All stereoisomers display at least an order of magnitude weaker binding to DNA than the control compound netropsin; however, a strong association with HSA was observed for the (4R,6S) stereoisomer.

METHODS OF TREATING LIVER DISEASES

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Synthesis and biological evaluation of potential 5-HT7 receptor PET radiotracers

Brain serotonin 7 receptor (5-HT7) is involved in several mood disorders and drug candidates targeting this subtype are currently in development. Positron emission tomography (PET) is a molecular imaging modality offering great promise for accelerating the process from preclinical discovery to clinical phases. As no PET radiopharmaceutical has yet been used successfully to study the 5-HT7 receptor in vivo, our objective is to develop the first 5-HT7 fluorine-18 labeled radiotracer. Four structural analogs of SB269970, a specific 5-HT7 receptor antagonist, divided in FP3 series and FPMP series were synthesized. Their antagonist effects were investigated by cellular functional assay. Nitro-precursors of these analogs were radiolabeled via a [18F-]nucleophilic substitution and in vitro autoradiographies were performed in rat brain. Chemical and radiochemical purities of fluorine radiotracers were >99% with specific activities in 40-129 GBq/μmole range. The four derivates presented antagonism potencies toward 5-HT7 receptors (pKB) between 7.8 and 8.8. The four PET radiotracers had suitable characteristic for 5-HT7 receptor probing in vitro even if the FP3 series seemed to be more specific for this receptor. These results encourage us to pursue in vivo studies.